Company Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder.
Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation.
The company was incorporated in 2012 and is based in New York, New York.
| Country | United States |
| Founded | 2012 |
| IPO Date | Nov 19, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 545 |
| CEO | Dr. Herriot Tabuteau M.D. |
Contact Details
Address: One World Trade Center, 22nd Floor New York, New York 10007 United States | |
| Phone | (212) 332-3241 |
| Website | axsome.com |
Stock Details
| Ticker Symbol | AXSM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001579428 |
| CUSIP Number | 05464T104 |
| ISIN Number | US05464T1043 |
| Employer ID | 45-4241907 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Herriot Tabuteau M.D. | Founder, Chairman, Chief Executive Officer and President |
| Nick Pizzie CPA, M.B.A. | Chief Financial Officer |
| Mark L. Jacobson | Chief Operating Officer and Secretary |
| Hunter Murdock Esq. | General Counsel and Secretary |
| Dr. Amanda Jones Pharm.D. | Senior Vice President of Clinical Development |
| Lori Englebert M.B.A. | Executive Vice President of Commercial and Business Development |
| Joseph Debrah-Afful CPA, M.B.A. | Director of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | 144 | Filing |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 19, 2024 | 8-K | Current Report |
| Mar 15, 2024 | 144 | Filing |
| Mar 14, 2024 | 144 | Filing |
| Feb 23, 2024 | 10-K | Annual Report |
| Feb 20, 2024 | 8-K | Current Report |
| Feb 20, 2024 | 8-K | Current Report |